UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

SCHEDULE 13G/A

Under the Securities Exchange Act of 1934 (Amendment No. 8)*

Amicus Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value \$0.01 per share (Title of Class of Securities)

03152W 10 9 (CUSIP Number)

December 31, 2021 (Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

□ Rule 13d-1(b)

図 Rule 13d-1(c)

□ Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

1							
	I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)						
	Perceptive A						
2			PPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)				
	(a)						
	CEC LICE O	ATT T					
3	SEC USE O	NLY					
4	CITIZENSHIP OR PLACE OF ORGANIZATION						
	Dalas						
	Delaware	5	SOLE VOTING POWER				
		5	SOLE VOTING POWER				
			0				
N	UMBER OF	6	SHARED VOTING POWER				
DE	SHARES	U	SHARED VOTING POWER				
	NEFICIALLY WNED BY		26,559,443				
	EACH	7	SOLE DISPOSITIVE POWER				
R	EPORTING	′	SOLL DIST CONTINUE TO WER				
PERSON			0				
	WITH:	8	SHARED DISPOSITIVE POWER				
			26,559,443				
9							
	26,559,443						
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)						
11	PERCENT (OF C	CLASS REPRESENTED BY AMOUNT IN ROW 9				
	9.5%						
12	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)						
	TA						
	IA						

1	1 NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)					
	, , , , , , , , , , , , , , , , , , ,					
	Joseph Edel					
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) □ (b) □					
	., .					
3	SEC USE ONLY					
4	CITIZENSHIP OR PLACE OF ORGANIZATION					
	United States of America					
		5	SOLE VOTING POWER			
NI	JMBER OF		0			
	SHARES	6	SHARED VOTING POWER			
	NEFICIALLY WNED BY		26,559,443			
	EACH	7	SOLE DISPOSITIVE POWER			
REPORTING						
PERSON WITH:		8	0 SHARED DISPOSITIVE POWER			
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		ð	SHARED DISPOSITIVE POWER			
			26,559,443			
9	9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON					
	26,559,443					
10		X II	THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)			
11	PERCENT (OF C	CLASS REPRESENTED BY AMOUNT IN ROW 9			
11	TLICLITI	J. (ZELIO IGERESELLES DE MINOCILE IL ROM S			
	9.5%					
12	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)					
	IN					

1	1 NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)						
	ARGO, IDENTIFICATION, NO. OF TEO VETEROUND (ENTITIES ONE)						
	Perceptive Life Sciences Master Fund, Ltd.						
2							
	(a) □ (l	b) [
3	SEC LISE O	NIT X	7				
3	SEC USE ONLY						
4	CITIZENSHIP OR PLACE OF ORGANIZATION						
	Cayman Islands						
		5	SOLE VOTING POWER				
N	UMBER OF SHARES	6	SHARED VOTING POWER				
BE	NEFICIALLY						
C	WNED BY		26,559,443				
	EACH	7	SOLE DISPOSITIVE POWER				
REPORTING PERSON							
WITH:		8	0 SHARED DISPOSITIVE POWER				
.,		0	SHARED DISPOSITIVE POWER				
			26,559,443				
9	9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON						
	26.550.442						
10	26,559,443						
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)						
11	PERCENT (OF C	CLASS REPRESENTED BY AMOUNT IN ROW 9				
	9.5%						
12	TYPE OF R	EPO	ORTING PERSON (SEE INSTRUCTIONS)				
	CO						
<u> </u>							

Item 1(a). Name of Issuer:

Amicus Therapeutics, Inc. (the "Issuer")

Item 1(b). Address of Issuer's Principal Executive Offices:

3675 Market Street, Philadelphia, PA 19104

Item 2(a). Names of Persons Filing:

The names of the persons filing this report (collectively, the "Reporting Persons") are:

Perceptive Advisors LLC ("Perceptive Advisors")

Joseph Edelman ("Mr. Edelman")

Perceptive Life Sciences Master Fund, Ltd. (the "Master Fund")

Item 2(b). Address of Principal Business Office or, if None, Residence:

The address of the principal business office of each of the Reporting Persons is:

51 Astor Place, 10th Floor New York, NY 10003

Item 2(c). <u>Citizenship</u>:

Perceptive Advisors is a Delaware limited liability company

Mr. Edelman is a United States citizen

The Master Fund is a Cayman Islands corporation

Item 2(d). <u>Title of Class of Securities</u>:

Common Stock, par value \$0.01 per share ("Common Stock")

Item 2(e). <u>CUSIP Number</u>:

03152W 10 9

Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

Not applicable.

Item 4. Ownership.

The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover page to this Schedule 13G. The ownership percentages reported are based on 278,645,807 outstanding shares of Common Stock, as reported in the Issuer's Form S-3ASR filed on November 9, 2021.

The Master Fund directly holds 26,559,443 shares of Common Stock. Perceptive Advisors serves as the investment manager to the Master Fund and may be deemed to beneficially own such shares. Mr. Edelman is the managing member of Perceptive Advisors and may be deemed to beneficially own such shares.

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following \Box .

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not applicable.

Item 7. <u>Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.</u>

Not applicable.

Item 8. <u>Identification and Classification of Members of the Group.</u>

Not applicable.

Item 9. <u>Notice of Dissolution of Group.</u>

Not applicable.

Item 10. <u>Certification</u>.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

Date: February 14, 2022

PERCEPTIVE ADVISORS LLC

By: /s/ Joseph Edelman

Name: Joseph Edelman Title: Managing Member

/s/ Joseph Edelman

JOSEPH EDELMAN

PERCEPTIVE LIFE SCIENCES MASTER FUND, LTD.

By: Perceptive Advisors LLC

By: /s/ Joseph Edelman

Name: Joseph Edelman Title: Managing Member

AGREEMENT

The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934.

Date: February 14, 2022

PERCEPTIVE ADVISORS LLC

By: /s/ Joseph Edelman

Name: Joseph Edelman Title: Managing Member

/s/ Joseph Edelman

JOSEPH EDELMAN

PERCEPTIVE LIFE SCIENCES MASTER FUND, LTD.

By: Perceptive Advisors LLC

By: /s/ Joseph Edelman

Name: Joseph Edelman Title: Managing Member

AGREEMENT

The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934.

Date: February 14, 2022

PERCEPTIVE ADVISORS LLC

By: /s/ Joseph Edelman

Name: Joseph Edelman Title: Managing Member

/s/ Joseph Edelman

JOSEPH EDELMAN

PERCEPTIVE LIFE SCIENCES MASTER FUND, LTD.

By: Perceptive Advisors LLC

By: /s/ Joseph Edelman

Name: Joseph Edelman Title: Managing Member